The elevated expression of PARK7 is significantly associated with the stage, grade, and poor progression-free survival of ovarian tumors [37], and is highly expressed along with phospho-AKT and mTOR in patients with ovarian cancer and peritoneal malignant effusions [51]. The gene discussed is PARK7; the disease is ovarian cancer.